Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Histologic tumor type and the rate of complete response after neoadjuvant therapy for esophageal cancer.

Bollschweiler E, Hölscher AH, Metzger R.

Future Oncol. 2010 Jan;6(1):25-35. doi: 10.2217/fon.09.133. Review.

PMID:
20021207
2.

Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.

Castoro C, Scarpa M, Cagol M, Ruol A, Cavallin F, Alfieri R, Zanchettin G, Rugge M, Ancona E.

Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.

PMID:
21556952
3.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
4.

Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.

Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S, Karl R.

Ann Surg Oncol. 2010 Apr;17(4):1159-67. doi: 10.1245/s10434-009-0862-1. Epub 2010 Feb 6.

PMID:
20140529
5.

Neoadjuvant chemotherapy or chemoradiotherapy for locally advanced esophageal cancer.

Smithers BM, Thomson I.

Thorac Surg Clin. 2013 Nov;23(4):509-23. doi: 10.1016/j.thorsurg.2013.07.005. Epub 2013 Oct 13. Review.

PMID:
24199701
6.

NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy.

Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, Kelleher D, Reynolds JV.

Ann Surg. 2004 Apr;239(4):491-500.

7.

Neoadjuvant paclitaxel poliglumex, cisplatin, and radiation for esophageal cancer: a phase 2 trial.

Dipetrillo T, Suntharalingam M, Ng T, Fontaine J, Horiba N, Oldenburg N, Perez K, Birnbaum A, Battafarano R, Burrows W, Safran H.

Am J Clin Oncol. 2012 Feb;35(1):64-7. doi: 10.1097/COC.0b013e318201a126.

PMID:
21297434
8.

Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.

Zanoni A, Verlato G, Giacopuzzi S, Weindelmayer J, Casella F, Pasini F, Zhao E, de Manzoni G.

Ann Surg Oncol. 2013 Jun;20(6):1993-9. doi: 10.1245/s10434-012-2822-4. Epub 2012 Dec 29.

PMID:
23274533
9.

Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer.

Hammoud ZT, Kesler KA, Ferguson MK, Battafarrano RJ, Bhogaraju A, Hanna N, Govindan R, Mauer AA, Yu M, Einhorn LH.

Dis Esophagus. 2006;19(2):69-72.

PMID:
16643172
10.

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS).

van Heijl M, van Lanschot JJ, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BP, Tilanus HW, Richel DJ, Busch OR, Bartelsman JF, Koning CC, Offerhaus GJ, van der Gaast A.

BMC Surg. 2008 Nov 26;8:21. doi: 10.1186/1471-2482-8-21.

11.

Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.

Spigel DR, Greco FA, Meluch AA, Lane CM, Farley C, Gray JR, Clark BL, Burris HA 3rd, Hainsworth JD.

J Clin Oncol. 2010 May 1;28(13):2213-9. doi: 10.1200/JCO.2009.24.8773. Epub 2010 Mar 29.

PMID:
20351330
12.

Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response.

Barbour AP, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, Burmeister B, Smithers BM.

Ann Surg Oncol. 2008 Oct;15(10):2894-902. doi: 10.1245/s10434-008-0084-y. Epub 2008 Jul 29.

PMID:
18663531
13.

[Preoperative radiochemotherapy of esophageal carcinoma. Light at the end of the tunnel?].

Hölscher AH, Metzger R, Schneider PM.

Zentralbl Chir. 2000;125(4):319-25. German.

PMID:
10829311
14.

Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer.

Vallböhmer D, Kuhn E, Warnecke-Eberz U, Brabender J, Hoffmann AC, Metzger R, Baldus SE, Drebber U, Hoelscher AH, Schneider PM.

Pharmacogenomics. 2008 Jun;9(6):681-90. doi: 10.2217/14622416.9.6.681.

PMID:
18518847
15.

High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.

Xi H, Baldus SE, Warnecke-Eberz U, Brabender J, Neiss S, Metzger R, Ling FC, Dienes HP, Bollschweiler E, Moenig S, Mueller RP, Hoelscher AH, Schneider PM.

Clin Cancer Res. 2005 Dec 1;11(23):8341-7.

16.

Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.

Huang TC, Hsu CH, Lin CC, Tu YK.

Jpn J Clin Oncol. 2015 Nov;45(11):1023-8. doi: 10.1093/jjco/hyv119. Epub 2015 Aug 5. Review.

PMID:
26246479
17.

Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States.

Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Gordon HS, Stewart AK, Ko CY, Bentrem DJ.

Cancer. 2012 Jul 1;118(13):3268-76. doi: 10.1002/cncr.26608. Epub 2011 Oct 17.

18.

Radiotherapy in the multimodality management of esophageal cancer.

Encheva E, Kolev N, Tonev A, Ignatov V, Shterev S, Petrov D, Zlatarov A, Koleva I, Chaushev B, Kirilova T, Ivanov K.

Khirurgiia (Sofiia). 2014;(3):12-9. Bulgarian, English.

PMID:
25799618
19.

Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer.

Reynolds JV, Muldoon C, Hollywood D, Ravi N, Rowley S, O'Byrne K, Kennedy J, Murphy TJ.

Ann Surg. 2007 May;245(5):707-16.

20.

Does neoadjuvant chemoradiation downstage esophageal carcinoma?

Slater MS, Holland J, Faigel DO, Sheppard BC, Deveney CW.

Am J Surg. 2001 May;181(5):440-4.

PMID:
11448438

Supplemental Content

Support Center